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Abstract: TGR5 is a G protein-coupled receptor expressed in
brown adipose tissue and muscle, where its activation by bile acids
triggers an increase in energy expenditure and attenuates diet-
induced obesity. Using a combination of pharmacological and genetic
gain- and loss-of-function studies in vivo, we show here that TGR5
signaling induces intestinal glucagon-like peptide-1 (GLP-1) release,
leading to improved liver and pancreatic function and enhanced glu-
cose tolerance in obese mice. In addition, we show that the induction
of GLP-1 release in enteroendocrine cells by 6a-ethyl-23(S)-methyl-
cholic acid (EMCA, INT-777), a speciﬁc TGR5 agonist, is linked to an
increase of the intracellular ATP/ADP ratio and a subsequent rise in
intracellular calcium mobilization. Altogether, these data show that
the TGR5 signaling pathway is critical in regulating intestinal GLP-
1 secretion in vivo, and suggest that pharmacological targeting of
TGR5 may constitute a promising incretin-based strategy for the
treatment of diabesity and associated metabolic disorders.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
‘‘The room is empty; this must be a bile acid meeting”
– quote by eminent hepatologist.
Bile acids have long been considered as nothing more than
emulsiﬁers of lipids. As such, bile acids could excite few hepatol-
ogists. However, it now appears that bile acids have important
and intriguing signalling functions and researchers from many
corners including the industry have come to see what is going on.
The story begins in the early 1980s when Bert O’Malley, Ron
Evans, Pierre Chambon, and others ﬁrst puriﬁed and later cloned
a number of hormone receptors [1–5]. These receptors allowed
the intercellular communication already predicted in 1975 by
Gordon Tomkins [6]. They were called nuclear hormone receptorsJournal of Hepatology 20
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E-mail address: p.l.jansen@amc.uva.nlregulation. In the mid nineties a member of the nuclear receptor
family, FXR, was identiﬁed and shown to be activated by farnesol,
a metabolite of cholesterol metabolism [7]. Shortly after the clon-
ing of FXR, David Moore and David Mangelsdorf (in two separate
publications in the same issue of Science) reported that bile acids
bind and activate FXR [8,9]. FXR turned out to be a pleiotropic
nuclear receptor with actions on bile acid synthesis and transport
processes [10–13]. More recently, metabolic, anti-inﬂammatory,
and anti-ﬁbrotic actions have been assigned to FXR [14–16].
Not only FXR but also the pregnane X-receptor (PXR), the consti-
tutive androstane receptor (CAR), and the vitamin D receptor
(VDR) are activated by primary (FXR) and secondary bile acids
(PXR, CAR, VDR) with effects on the expression of enzymes of
the cytochrome P-450 family (CYP3A4, CYP2B6, CYP2C9), UDP-
glucuronosyltransferase (UGT 1A1), glutathionetransferase
(GSTA1/A2), ABC transporters (ABCB11, ABCG2, MDR1, MRP2,
MRP3, MRP4), and other transport proteins such as the organic
anionic transport proteins OATP1B1, OATP1B3, OATP2B1, and
the organic solute transporter OSTa/b [17–21].
A new twist to the story came in 2002 when Japanese investi-
gators discovered a bile salt-speciﬁc G protein-coupled receptor
(GPCR). The GPCRs are membrane surface receptors that are acti-
vated by external ligands [22]. GPCRs are members of a very large
protein superfamily. These proteins are evolutionarily well con-
served and comprise 40–50 taste and 500–1000 odorant recep-
tors, including receptors for pheromones. Maruymama and
Kawamata discovered that bile acids activate a member of the
GPCR family [23,24]. This member was ﬁrst called M-BAR or
BG37 but now has adopted the name TGR5. TGR5 is expressed
in placenta, spleen, lung, mammary gland, stomach, small intes-
tine, colon, adipose tissue, liver, adrenal glands, kidney, skeletal
muscle, and pituitary gland. Taurolithocholic acid, lithocholic acid,
and deoxycholic acid have the greatest afﬁnity for the receptor fol-
lowed by chenodeoxycholic acid, cholic acid, and ursodeoxycholic
acid. In a seminal paper in 2006 by the Auwerx group, it was
shown that activation of TGR5 in brown adipocytes and human
skeletal myocytes stimulates the thyroid hormone activating
enzyme type 2 iodothyronine deiodinase in a cyclic-AMP-depen-
dent way [25]. This stimulates mitochondrial activity and oxygen
consumption and therefore energy expenditure. Recently, in 2009,
the same group reported that TGR5 plays a critical role in the
release of glucagon-like peptide-1, a hormone that controls glu-
cose homeostasis [26]. GLP-1 stimulates insulin production and
secretion in pancreas beta cells and inhibits glucagon secretion.
TGR5 research was greatly helped by the development of
potent and selective agonists like the cholic acid derivative, 6a-10 vol. 52 j 937–938
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ethyl-23(S)-methyl-cholic acid (INT-777) by Pellicciari [27]. This
agent, that has no FXR activity, stimulates cAMP production,
increases oxygen consumption, increases the ATP/ADP ratio, and
activates cytochrome c oxidase in enteroendocrine L cells. Further-
more, INT-777 increases intracellular calcium levels and stimu-
lates GLP-1 release. These effects disappear when TGR5 is
knocked out by siRNA. Thomas et al. show that insulin sensitivity
in TGR5 knock-outmice on a high fat diet (HFD) is abnormal while
in TGR5-transgenic mice on HFD, glucose tolerance and insulin
sensitivity is restored. Pancreas islets in wild-type and TGR5/
mice on HFD, look hypertrophic and insulin-depleted while in
TGR5-transgenic mice on HFD, the islets look normal and insu-
lin-rich. This may be related to GLP-1 secretion, which is reduced
in TGR5/ and increased in TGR5-transgenic mice. These effects
could be reproduced in pharmacologic intervention studies.
Weight gain, liver fatmass andelevated transaminaseswere atten-
uated in mice on HFD receiving INT-777. INT-777 caused an
increase in energy expenditure as measured by increased oxygen
consumption, increased mitochondrial enzymes, and increased
deiodinase gene expression and restored insulin sensitivity [26].
These elegant studies show that activation of the bile acid
receptor TGR5 has a profound and important effect on glucose
homeostasis. In another recent study the Auwerx group extended
these observations to humans. In this new study Patti et al. provide
suggestive evidence that the improvement of glucose metabolism
in obese patients after gastric bypass surgery may be due to
slightly elevated bile acid levels, which may stimulate TGR5 [28].
For hepatologists these studies are food for thought. Although
metabolism in mice and men shows considerable differences (see
for instanceSchaapetal. [29])onemayask ifdisturbancesofbileacid
signallingmaycontribute to theaetiologyofnon-alcoholic fatty liver
disease. Would TGR5 agonists be helpful in the treatment of NAFLD
or NASH? Perhaps yes, but the effect of INT-777 on thyroidmetabo-
lism may also be reason for concern as it may induce a state of
(mild?) hyperthyroidism.What happens to cholestatic liver disease
whenbileacids areelevated?Would that leadtostimulationofTGR5
and an overstimulation of energy expenditure? Does this perhaps
explain the weight loss often seen in these patients? Traditionally,
this has been attributed to a lack of bile acids in the intestine for
digestionof fat but theworkof JohanAuwerx suggests analternative
view. Elevated bile acid levels may cause overstimulation of metab-
olism. Thus, treatment with ursodeoxycholic acid and/or bile acid
sequestering agentsmay improvemetabolism and counteract anor-
exia by lowering serum levels of primary bile acids in patients with
cholestatic liver disease.Conﬂicts of interest
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